Interferon alfa-2b therapy may be associated with a number of adverse effects that are unpleasant but which do not preclude continued therapy. Because lower doses may be less effective, reducing or stopping the drug is not recommended unless a serious reaction (hematologic toxicity, severe depression or cardiac ischemia) occurs. A number of adjustments can make less serious adverse reactions more tolerable.
